TY - JOUR
T1 - Cellular and molecular pathobiology of pulmonary arterial hypertension
AU - Humbert, Marc
AU - Morrell, Nicholas W.
AU - Archer, Stephen L.
AU - Stenmark, Kurt R.
AU - MacLean, Margaret R.
AU - Lang, Irene M.
AU - Christman, Brian W.
AU - Weir, E. Kenneth
AU - Eickelberg, Oliver
AU - Voelkel, Norbert F.
AU - Rabinovitch, Marlene
PY - 2004/6/16
Y1 - 2004/6/16
N2 - Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction, remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary vascular resistance in PAH. The process of pulmonary vascular remodeling involves all layers of the vessel wall and is complicated by cellular heterogeneity within each compartment of the pulmonary arterial wall. Indeed, each cell type (endothelial, smooth muscle, and fibroblast), as well as inflammatory cells and platelets, may play a significant role in PAH. Pulmonary vasoconstriction is believed to be an early component of the pulmonary hypertensive process. Excessive vasoconstriction has been related to abnormal function or expression of potassium channels and to endothelial dysfunction. Endothelial dysfunction leads to chronically impaired production of vasodilators such as nitric oxide and prostacyclin along with overexpression of vasoconstrictors such as endothelin (ET)-1. Many of these abnormalities not only elevate vascular tone and promote vascular remodeling but also represent logical pharmacological targets. Recent genetic and pathophysiologic studies have emphasized the relevance of several mediators in this condition, including prostacyclin, nitric oxide, ET-1, angiopoietin-1, serotonin, cytokines, chemokines, and members of the transforming-growth-factor-beta superfamily. Disordered proteolysis of the extracellular matrix is also evident in PAH. Future studies are required to find which if any of these abnormalities initiates PAH and which ones are best targeted to cure the disease.
AB - Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction, remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary vascular resistance in PAH. The process of pulmonary vascular remodeling involves all layers of the vessel wall and is complicated by cellular heterogeneity within each compartment of the pulmonary arterial wall. Indeed, each cell type (endothelial, smooth muscle, and fibroblast), as well as inflammatory cells and platelets, may play a significant role in PAH. Pulmonary vasoconstriction is believed to be an early component of the pulmonary hypertensive process. Excessive vasoconstriction has been related to abnormal function or expression of potassium channels and to endothelial dysfunction. Endothelial dysfunction leads to chronically impaired production of vasodilators such as nitric oxide and prostacyclin along with overexpression of vasoconstrictors such as endothelin (ET)-1. Many of these abnormalities not only elevate vascular tone and promote vascular remodeling but also represent logical pharmacological targets. Recent genetic and pathophysiologic studies have emphasized the relevance of several mediators in this condition, including prostacyclin, nitric oxide, ET-1, angiopoietin-1, serotonin, cytokines, chemokines, and members of the transforming-growth-factor-beta superfamily. Disordered proteolysis of the extracellular matrix is also evident in PAH. Future studies are required to find which if any of these abnormalities initiates PAH and which ones are best targeted to cure the disease.
KW - 5-HT
KW - 5-hydroxytryptamine
KW - BMP
KW - ET
KW - NO
KW - PAH
KW - TGF-β
KW - TGF-βR2
KW - VEGF
KW - bone morphogenetic proteins
KW - endothelin
KW - nitric oxide
KW - pulmonary arterial hypertension
KW - transforming growth factor-beta
KW - transforming growth factor-beta type-2 receptor
UR - http://www.scopus.com/inward/record.url?scp=2942541475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942541475&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2004.02.029
DO - 10.1016/j.jacc.2004.02.029
M3 - Article
C2 - 15194174
AN - SCOPUS:2942541475
SN - 0735-1097
VL - 43
SP - S13-S24
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 12 SUPPL.
ER -